Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease. - Wikidata - awgldk - TriplyDB

Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease.

Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease.

http://www.wikidata.org/entity/Q38306848

about

Assessment of Alzheimer's disease case-control associations using family-based methods Endothelin-converting enzymes and related metalloproteases in Alzheimer's disease The influence of chronic cerebral hypoperfusion on cognitive function and amyloid β metabolism in APP overexpressing mice Angiotensin-converting enzyme overexpression in myelomonocytes prevents Alzheimer's-like cognitive decline Alterations in synaptic plasticity coincide with deficits in spatial working memory in presymptomatic 3xTg-AD mice.Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease.An association analysis of Alzheimer disease candidate genes detects an ancestral risk haplotype clade in ACE and putative multilocus association between ACE, A2M, and LRRTM3.Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process.ACE variants and association with brain Aβ levels in Alzheimer's disease Identification and characterization of Aβ peptide interactors in Alzheimer's disease by structural approaches.Renin angiotensin system and gender differences in dopaminergic degeneration.Granulocyte-colony stimulating factor attenuates oligomeric amyloid β neurotoxicity by activation of neprilysin.Telmisartan Modulates Glial Activation: In Vitro and In Vivo Studies The Role of the Renin-Angiotensin System in Amyloid Metabolism of Alzheimer's Disease Secreted APP regulates the function of full-length APP in neurite outgrowth through interaction with integrin beta1.Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease.ACE inhibition with captopril retards the development of signs of neurodegeneration in an animal model of Alzheimer's disease Current and future therapy in Alzheimer's disease.The AbetaCs of Abeta-cleaving proteases.Angiotensin converting enzyme inhibitors and Alzheimer disease in the presence of the apolipoprotein E4 allele.Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors.Current perspectives on pharmacotherapy of Alzheimer's disease.Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease?The beneficial role of vitamin D in Alzheimer's disease.New and emerging treatments for Alzheimer's disease.New and emerging treatments for Alzheimer's disease.Proteolytic degradation of amyloid β-protein.The role of Beta-adrenergic receptor blockers in Alzheimer's disease: potential genetic and cellular signaling mechanisms.Aβ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes.Neurovascular and Cognitive failure in Alzheimer's Disease: Benefits of Cardiovascular Therapy.Progress in the development of new drugs in Alzheimer's disease.Angiotensin II protects against alpha-synuclein toxicity and reduces protein aggregation in vitro.Zinc metalloproteinases and amyloid Beta-Peptide metabolism: the positive side of proteolysis in Alzheimer's disease.Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes.Angiotensin II-inhibition: effect on Alzheimer's pathology in the aged triple transgenic mouse.Angiotensin II-inhibiting drugs have no effect on intraneuronal Aβ or oligomeric Aβ levels in a triple transgenic mouse model of Alzheimer's disease.Genetic variation in MME in relation to neprilysin protein and enzyme activity, Aβ levels, and Alzheimer's disease risk.Physiological and pathophysiological functions of different angiotensins in the brain.Exceptional in vivo catabolism of neurodegeneration-related aggregates.Neprilysin, cardiovascular, and Alzheimer's diseases: the therapeutic split?

P2860

Q24622654-68756858-F4AD-459D-A76E-E67836DC6A84 Q26862901-6988420C-1886-41A0-A582-31F6BEC441CB Q30477118-95DE8607-E7C9-4369-B8A2-C5C52E9005E2 Q30572684-27066DFC-BAE2-4098-94D9-7ABA1C788D8C Q30678146-C3B663A6-22A3-4864-A389-8B8355906D10 Q30833707-569C26FD-870B-4326-8676-E9358A3FF6C0 Q33652202-4CA196EA-D4F9-44D3-9008-A8C5987EB6A6 Q34110227-79F80D79-E044-4FAF-9F1A-C049F9AAFD56 Q34310258-83530946-7CA7-4555-BB88-374871D789B0 Q34312807-921379DB-4C65-4E3D-8420-32CB19C81F4D Q35203828-7FAC7279-E286-4BCD-BAA4-1779FC6B4BA6 Q35213148-70F4AEE4-8457-4C71-B551-D2DB34C30FE9 Q36019970-C2CF7B5E-3B72-4A14-AA28-52F06327E654 Q36721915-067A86ED-5DB2-41BC-AA0F-C63A66975158 Q36740945-0CDB2C73-B1F0-452D-823A-BFFC8418C3AF Q36764094-55832EC1-2610-4B70-A467-AC38412F628B Q37139242-C06D14C5-70A1-492C-BDC6-7BA5144BEF93 Q37165703-F571003F-4895-4168-83E6-E92E6C209588 Q37250796-2EB06221-923A-44E9-8E8A-5D4DE5D12A79 Q37415248-2AB4635B-867A-453C-B0AF-E10ABD3F8AAD Q37600876-2E94B004-8182-4068-AD40-DA6B09B5AD9F Q37827489-61F0B41D-C587-4891-A4E7-2530C1D299AB Q37961852-B668DA01-8281-46EE-90B7-D25DDEA9E08C Q37971804-C4B821C7-7C2E-41B5-BC87-A9FEF9186E4A Q37996072-BE1A8026-8313-43B6-B9D6-901B5AC81ED7 Q38006979-6229B425-0E5A-4316-AC56-203DA5A63E8A Q38016899-DC425B65-5CA8-4DC0-A9E1-E8CD3B3F90C2 Q38108100-BFE567BA-E5C1-45A0-89F4-6AD0F87E9D9A Q38259551-2F8393F7-5C7F-4114-80D9-796F9B3047A0 Q38781022-6CE569AA-353B-46F8-B898-6CF1D0CDEA56 Q39789745-8CCBB641-C1B3-4D96-8C50-347D15EE95EA Q40075301-EC627F92-554D-416B-B185-7C15529EFBB3 Q41680485-DF15C085-B116-443B-A32D-835B616773EA Q41840991-F79244EC-FFF5-42A3-A568-0C6399584D25 Q42069095-A7DE3D2A-93B4-41B8-A77A-B6E19B074843 Q42069122-A2D779B4-FC7A-4E9F-AE7D-8C4A53E0C19C Q42561537-E4130054-144A-4C84-9635-F4F23AB2556A Q46322831-B3154A4D-B771-4ABA-A889-77AFB0EE533A Q48043354-D3A4AECB-37DB-41B1-B094-606B9915671C Q48352528-363FE06B-1578-47E5-A57D-EAEB6911358A

P2860

Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease.

http://www.wikidata.org/entity/Q38306848

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Effects of prolonged angiotens ...... e models of Alzheimer disease.

@en

type

label

Effects of prolonged angiotens ...... e models of Alzheimer disease.

@en

prefLabel

Effects of prolonged angiotens ...... e models of Alzheimer disease.

@en

P1433

Q38306848-D90CD905-3988-42C5-A4EA-1B579458BB6D

P1476

Q38306848-5751BE32-463F-446B-B013-0BDECE290143

P2093

Q38306848-255217DC-FADF-4F22-A48B-90E492D0F74E

Q38306848-2CF9F8AF-AA1E-4DAF-B5CB-66648C4004CA

Q38306848-57D37B00-F1BC-4AE9-990F-9FEE38AE798F

P2860

Q38306848-0174B732-A4F1-4A83-A37F-A5B34701EA83

Q38306848-0D1FAE7B-F971-4DDB-B909-924CD9281F7B

Q38306848-0F8ECFB8-5166-4E84-B762-4FCC8D8DB358

Q38306848-10F71745-26A7-45D4-8A43-FC36558FA10F

Q38306848-1A425D24-D429-4B73-AE99-BEE2B99B0C8E

Q38306848-281BE320-4CEF-46B7-8935-38500FE9A714

Q38306848-34FC5A5E-97AC-4144-B584-CF98BA1EF812

Q38306848-49F7CE54-BC6D-4FA7-8388-291416BE1535

Q38306848-61EDC429-5D08-4A57-812E-568F462D2996

Q38306848-6D2F6CC6-7C39-47CE-878B-D54418C64857

P304

Q38306848-C5BC4D05-7D1A-4930-9B41-92F264EAC441

P31

Q38306848-3251CFDF-AE9E-4388-BC4F-ADA08EC5CEA4

P356

Q38306848-A2318260-783F-4C69-91FC-3F36F112E5EE

P433

Q38306848-68E64A61-2182-4394-AFC7-4A64B9E5B0F1

P478

Q38306848-4D6B5913-5F37-4819-908E-43AFA96BE338

P577

Q38306848-73C11127-F94D-4DFE-A79E-F0227AF3A011

P5875

Q38306848-49729E51-4061-432E-B39D-9888AC690A81

P698

Q38306848-B89B369B-25D6-44AA-AD23-973FE9CD178A

P921

Q38306848-02E78E00-6B8E-4E40-8408-01FDAF83F9C7

P932

Q38306848-FD946728-10C0-46C8-BEA9-CFE144C57132

P356

J.NBD.2007.01.004

P1433

Neurobiology of Disease

P1476

Effects of prolonged angiotens ...... e models of Alzheimer disease.

@en

P2093

Dennis J Selkoe

http://www.w3.org/2001/XMLSchema#string

Matthew L Hemming

http://www.w3.org/2001/XMLSchema#string

Wesley Farris

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of the human angiotensin-converting enzyme-lisinopril complex

Degradation of the amyloid beta-protein by the novel mitochondrial peptidasome, PreP

Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease

Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo

Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease

Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme

Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction

High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation

Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta ); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity.

Systemic catabolism of Alzheimer's Abeta40 and Abeta42.

P304

273-281

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NBD.2007.01.004

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6484060

http://www.w3.org/2001/XMLSchema#string

P698

17321748

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

2377010

http://www.w3.org/2001/XMLSchema#string